Incode Secures $220M for Its Series B, Earning Unicorn Status Less Than Seven Months Following Its Series A Round
Incode, the next-generation identity verification and authentication platform for global enterprises, today announced it has raised $220 million in equity for its Series B funding round, giving the company a $1.25 billion valuation and propelling it to unicorn status less than seven months following its Series A round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005262/en/
Incode’s spectacular rate of growth – it grew 6x in revenues over the last 12 months – is driving the latest cycle of investments, which comes on top of the company raising $25 million Series A funding in March. The level of fundraise validates Incode’s leadership in the global digital identity solutions market and its groundbreaking, automated AI-based approach to reinvent the customer experience of the future.
“Our ‘One Identity Everywhere’ vision is transforming the way humans experience their identity journeys with companies,” said Ricardo Amper, Founder and CEO of Incode Technologies. “We have created an experience that is so seamless and frictionless, it brings that ‘Wow’ moment to the end customer when onboarding to a new bank, checking into a hotel or being admitted to a hospital. By reinventing these experiences, we are building trust and creating delight between enterprises and their customers.”
This latest investment round was led by marquee investors General Atlantic and SoftBank, with additional investment from top-tier financial institutions J.P. Morgan, Capital One Ventures and Coinbase Ventures. Rounding out the fundraise are SVCI (Silicon Valley CISO Investments), a group of over 50 leading technology CISOs that are joining forces and funds to invest in the next generation of cybersecurity innovation, and the founders of dLocal, with participation from existing investors DN Capital, 3L Capital, Framework Ventures, Dila Capital and others.
What makes Incode unique in the crowded digital identity space?
- Incode offers a full omnichannel orchestration platform that allows companies to have a single integration point to solve the identity problem – from onboarding customers in a frictionless and secure way to seamlessly authenticating them once they’re onboarded.
- Incode’s solution is fully automated, meaning it doesn’t use humans in call centers to identify clients. The reality is that today machines are much better than humans both in terms of speed, privacy and accuracy, enabling Incode to deliver real-time responses with much less fraud.
- Incode owns its entire technology stack, instead of using sub-vendors like many of its competitors. This creates a direct relationship between the enterprise and the technology owner, which allows Incode to continually improve its tech based on customer feedback.
- This direct relationship enables Incode to build true partnerships with its customers. “Incode is a key strategic partner in helping us to address our identity needs at scale. Incode offers the right combination of world-class technology, security and seamless experience for our clients,” said Miguel Lavalle, Account Opening Head at Citi.
“Incode is a leader in the digital identity space and has developed a robust solution to address some of the industry’s most significant challenges, particularly around frictionless, secure onboarding and authentication. The company’s unique platform and technology has powered its growth to date, and we look forward to partnering with and supporting Incode as it helps drive the future of identity solutions,” said Martin Escobari, Co-President, Managing Director and Head of General Atlantic’s business in Latin America.
“We are very excited to support Ricardo and all of his amazing team at Incode as they continue expanding globally through enterprise clients, including many of our portfolio companies. Incode provides a world-class suite of digital onboarding and authentication tools, helping its clients manage customer identities while scaling trust and reducing friction,” said Paulo Passoni, Managing Partner of SoftBank Latin America funds.
"The biggest impact that Incode and the identity industry in general can have is to generate trust between people, companies and institutions,” said Amper. “Without trust, interest rates are set higher, processes get complicated, and business becomes more difficult. Trust is the core element that opens financial systems to everyone and allows many more people to participate in a democratic system. At Incode, we create trust by eliminating barriers, reducing costs and democratizing access.”
To learn more about Incode, visit incode.com.
About Incode Technologies
Incode is a leading identity company that is reinventing the way humans verify their identity and interact with the world’s largest companies with a highly secure and delightful AI-based experience. Incode’s end-to-end fully automated orchestration platform enables seamless access across multiple channels with products focused on onboarding, authentication and payment verification that increase conversion and reduce fraud.
With its mission to build trust and democratize access, Incode works with a number of the world’s biggest banks, fintechs, hotels, governments and marketplaces. Incode is based in San Francisco with offices in Europe and Latin America.
About General Atlantic
General Atlantic is a leading global growth equity firm with more than four decades of experience providing capital and strategic support for over 445 growth companies throughout its history. Established in 1980 to partner with visionary entrepreneurs and deliver lasting impact, the firm combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to scale innovative businesses around the world. General Atlantic currently has over $86 billion in assets under management, inclusive of all products as of September 30, 2021, and more than 215 investment professionals based in New York, Amsterdam, Beijing, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, Singapore and Stamford. For more information on General Atlantic, please visit the website: www.generalatlantic.com.
About SoftBank Group
The SoftBank Group invests in breakthrough technology to improve the quality of life for people around the world. The SoftBank Group is comprised of SoftBank Group Corp. (TOKYO: 9984), an investment holding company that includes stakes in telecommunications, internet services, AI, smart robotics, IoT and clean energy technology providers; the SoftBank Vision Funds, which are investing more than US$135 billion to help extraordinary entrepreneurs transform industries and shape new ones; the US$5 billion SoftBank Latin America Fund, the largest venture fund in that region; the newly-launched US$3 billion SoftBank Latin America Fund II; and the SB Opportunity Fund, a US$100 million fund dedicated to investing in enterprises founded by entrepreneurs of color in the U.S. To learn more, please visit https://group.softbank/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Specifica Validates Best-in-Class Status for in vitro Antibody Discovery Platform in Two Key Peer Reviewed Publications29.1.2022 02:00:00 EET | Press release
Specifica, a privately held antibody engineering company focused on innovative in vitro antibody library and discovery tools, announced the publication of two peer-reviewed articles describing its Generation 3 Antibody Discovery Platform1,2. Antibodies are the fastest growing class of therapeutics, representing nine of the top twenty best-selling drugs3. The global antibody therapy market is projected to grow from $178.50 billion in 2021 to $451.89 billion in 2028 at a CAGR of 14.1%4. Traditionally, therapeutic antibodies have been generated by harvesting immune responses, either from in-bred or transgenic mice, or from immune human subjects. Although there has been a long-standing interest in using in vitro antibody library approaches that avoid the use of animals, there have been two main concerns with antibodies from in vitro libraries: binding affinities tend to be lower, and poor developability characteristics are common, complicating their development as successful drugs. As desc
ADVA Optical Networking SE: Acorn HoldCo, Inc. reaches minimum acceptance threshold for its public exchange offer to all shareholders of ADVA Optical Networking SE29.1.2022 01:45:00 EET | Press release
ADTRAN, Inc. today announced that by the end of the acceptance period on January 26, 2022, 24:00 hours (local time Frankfurt am Main), the voluntary public takeover offer of Acorn HoldCo, Inc. (“Bidder”) to all shareholders of ADVA Optical Networking SE (“ADVA“) has been accepted for more than 60% of all ADVA shares entitled to voting rights and existing as of October 31, 2021. The minimum acceptance threshold has therefore been reached. The final result as at the end of the acceptance period is expected to be published on January 31, 2022. ADTRAN, Inc. and ADVA have thus reached yet another important milestone for the merger of the two companies and have come closer to their goal of creating a leading company in the field of optical transmission technology for enterprise, access and wide-area networks. The consummation of the public exchange offer continues to be subject to closing conditions not yet fulfilled, especially foreign direct investment approval in Germany. ADVA shareholder
causaLens Raises $45m Series A to Scale Human-centered AI That Understands Cause-and-effect28.1.2022 17:46:00 EET | Press release
causaLens, the London deep tech company delivering the future of AI, has raised a $45m Series A round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005888/en/ The causaLens co-founders, Dr. Maksim Sipos, CTO, on the left, and Dr. Darko Matovski, CEO, on the right. (Photo: Business Wire) causaLens is the pioneer of Causal AI - the only AI technology quantifying cause-and-effect relationships to reason alongside humans in a manner that is trustworthy, explainable, and fair. Causal AI represents a giant leap ahead of current correlation-based AI technologies, which blindly extrapolate historical data and are unable to ask counterfactual questions — the ‘what ifs’ at the core of human imagination and creativity. causaLens’s no-code platform delivers far more accurate and reliable results, and allows humans and machines to work together for the first time. It is trusted by decision makers across finance, industry, technol
Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium28.1.2022 15:47:00 EET | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added 177Lu (n.c.a. 177Lu) cutting-edge production technology LuMagic®. This agreement will enable transfer of relevant equipment and supply from Monrol to Curium. Monrol is one of the few producers of Lutetium-177 n.c.a worldwide, having uninterrupted worldwide supply capabilities. Monrol Lu-177 n.c.a production process is an exclusive processing technology having cleaner and safer production method with stable isotope enrichment capability. Curium planning to manufacture the product Lu-177 n.c.a in its Petten production facility, Netherlands. This licence is offering significant opportunities both for Curium; one of the world’s largest nuclear medicine companies and Monrol; a company which develops, manufactures, and distributes world-class radiopharmaceutical products, radioisotopes to improve qu
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction28.1.2022 15:26:00 EET | Press release
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.1 Empagliflozin was previously approved for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).4 If approved, the positive opinion would expand this indication to be applicable for adults across the full spectrum of left ventricular ejection fraction (LVEF), including preserved ejection fraction (HFpEF). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005861/en/ “For the very first time, we now have a treatment that will improve clinical results across the full spectrum of heart failure patients – regardless of ejection fraction,” said Professor Stefan Anker, Heart Failure Car
Schlumberger DELFI Digital Platform Selected by Northern Lights JV for CO2 Project28.1.2022 15:00:00 EET | Press release
Schlumberger will deploy the DELFI* cognitive E&P environment on the Norwegian CO2 project by the Northern Lights Joint Venture (NL), to streamline subsurface workflows and longer-term modeling and surveillance of CO2 sequestration. NL was established to develop the world’s first open-source CO2 transport and storage infrastructure, providing accelerated decarbonization opportunities for European industries, with an ambition to store up to 5 million tonnes of CO2 per year based on market demand. For CO2 transportation and storage, Schlumberger digital solutions are used for subsurface characterization and dynamic reservoir simulation, which are key to understanding storage site capacity and the potential for injecting and containing fluids. They are also used for development planning, operations, appraisals, and monitoring purposes. “Northern Lights has recognized the huge potential of Schlumberger’s digital technology to fast-track decision making and de-risk CO2 transportation and st
Pixis Appoints Neel Pandya as the CEO for Europe Business, in Addition to APAC28.1.2022 14:28:00 EET | Press release
Pixis (formerly known as Pyxis One), a leading provider of contextual codeless AI infrastructure for complete marketing optimization, today appointed Neel Pandya as the Chief Executive Officer of its operations in Europe, in addition to his responsibilities of leading the APAC business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220128005166/en/ Neel Pandya joined Pixis as the CEO of APAC in its Bengaluru office after exiting L'Oréal. (Photo: Business Wire) Neel joined Pixis in its Bengaluru office in July 2021 as the CEO of APAC, bringing immense change and progress to the way Pixis operates, and greatly streamlining expansions in the APAC region. Under his leadership, Pixis witnessed a 185% growth in revenue in the APAC region, with India independently recording a 150% of growth. Over the last 7 months, in addition to greatly stabilizing customer churn Neel has also been instrumental in adding close to 30 new enterpris
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom